Bintrafusp alfa is under clinical development by Merck and currently in Phase III for Gallbladder Cancer. According to GlobalData, Phase III drugs for Gallbladder Cancer have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bintrafusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bintrafusp alfa overview
Bintrafusp alfa is under development for the treatment of metastatic or locally advanced urothelial cancer, metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) , recurrent and metastatic olfactory neuroblastoma, triple negative breast cancer, recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC), epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, metastatic pancreatic ductal adenocarcinoma (PDAC), metastatic urothelial carcinoma, metastatic or locally advanced solid tumors including castration-resistant prostate cancer and HPV associated tumors, melanoma, pancreatic cancer, glioblastoma multiforme, squamous cell carcinoma of the head and neck, recurrent respiratory papillomatosis, biliary tract cancer, oropharyngeal cancer, metastatic triple negative breast cancer, HER2 positive breast cancer, small cell lung cancer, squamous cell rectal cancer, vulvar cancer, anal cancer, vaginal cancer, penile cancer, neuroendocrine cancer, kaposi sarcoma, soft tissue sarcoma, colorectal cancer, non-small cell lung cancer, cervical cancer, metastatic non-prostate genitourinary malignancies including bladder cancer, kidney cancer, genital cancer, urinary tract cancer, thymoma and thymic carcinoma. It is a bifunctional fusion protein. It is administered through intravenous route. It is a new biological entity. It acts by targeting PD-L1 and TGF-Beta. It was also under development for the treatment of metastatic pancreatic adenocarcinoma, gastric cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma.
Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.
For a complete picture of Bintrafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.